0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%

Rallybio Corp

Healthcare US RLYB

1.01USD
0.03(3.46%)

Last update at 2024-12-19T18:57:00Z

Day Range

0.931.02
LowHigh

52 Week Range

1.239.14
LowHigh

Fundamentals

  • Previous Close 0.98
  • Market Cap66.32M
  • Volume72762
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-76.89900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.88

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -65.57900M -45.50800M -24.94000M -17.46000M
Minority interest - - - -
Net income -66.48700M -47.01000M -24.92500M -17.62600M
Selling general administrative 27.20M 18.74M 7.67M 6.28M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.17M 0.11M 0.06M 0.03M
Ebit -67.88400M -45.64800M -25.30300M -17.64200M
Ebitda -65.57900M -45.49800M -24.82900M -17.39500M
Depreciation and amortization 2.31M 0.15M 0.47M 0.25M
Non operating income net other 1.02M -1.35500M - -
Operating income -67.88400M -45.64800M -25.30300M -17.64200M
Other operating expenses 67.88M 45.65M 25.30M 17.64M
Interest expense 2.31M 0.01000M 0.05M 0.04M
Tax provision - 0.00000M -0.01500M 0.00000M
Interest income 1.96M 0.05M 0.17M 0.20M
Net interest income 1.96M 0.04M 0.12M 0.16M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.91M 1.50M -0.01500M 0.17M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 67.88M 45.65M 25.30M 17.64M
Cost of revenue - - - -
Total other income expense net 2.31M 0.14M 0.36M 0.18M
Discontinued operations - - - -
Net income from continuing ops -65.57900M -45.50800M -26.44700M -17.56300M
Net income applicable to common shares -66.65400M -45.50800M -26.44700M -17.56300M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 115.62M 180.44M 182.19M 141.86M 21.61M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.86M 1.05M 5.54M 1.03M 1.46M
Total liab 9.44M 11.12M 6.58M 187.88M 41.89M
Total stockholder equity 106.18M 169.32M 175.60M -47.01400M -20.56700M
Deferred long term liab - - - - -
Other current liab 8.07M 9.45M 5.95M 4.26M 2.95M
Common stock 0.00400M 0.00400M 0.00300M 0.45M 0.23M
Capital stock 0.00400M 0.00400M 0.00300M - -
Retained earnings -235.24500M -160.68100M -94.02700M -47.01400M -20.56700M
Other liab - - 0.03M 0.01M 0.94M
Good will - - - - -
Other assets - - 182.19M - -
Cash 24.49M 56.96M 175.33M 140.23M 19.46M
Cash and equivalents - - - - -
Total current liabilities 9.26M 10.74M 6.55M 5.84M 3.81M
Current deferred revenue - - - - -
Net debt -24.10200M -56.40300M -175.33400M -140.23300M -19.45800M
Short term debt 0.22M 0.18M - - -
Short long term debt - - - - -
Short long term debt total 0.39M 0.56M - - -
Other stockholder equity 341.41M 330.21M 269.63M 47.01M 20.57M
Property plant equipment - 0.39M 0.51M 0.29M 0.20M
Total current assets 114.79M 179.50M 180.87M 141.26M 20.92M
Long term investments 0.24M 0.03M 0.81M 0.31M 0.49M
Net tangible assets - 169.32M 175.60M -46.02400M -20.28100M
Short term investments 85.44M 112.04M - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.98M 1.11M 0.60M 1.58M 0.86M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01M -0.21400M - - -
Additional paid in capital - - - - -
Common stock total equity - 0.00400M 0.00300M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -160.68100M -94.02700M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.24M 0.03M 0.81M - -
Deferred long term asset charges - - - - -
Non current assets total 0.83M 0.94M 1.32M 0.60M 0.69M
Capital lease obligations 0.39M 0.56M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -112.11600M -2.00000M -1.93500M -1.93500M
Change to liabilities 3.71M 0.73M 0.72M 0.73M
Total cashflows from investing activities -112.17000M -2.33300M -2.07200M -0.18800M
Net borrowings - - - -
Total cash from financing activities 51.08M 82.97M 144.89M 31.57M
Change to operating activities -1.42300M -2.80300M 1.40M 1.34M
Net income -66.65400M -47.01300M -26.44700M -17.56300M
Change in cash -118.37600M 35.10M 120.78M 16.35M
Begin period cash flow 175.33M 140.23M 19.46M 3.10M
End period cash flow 56.96M 175.33M 140.23M 19.46M
Total cash from operating activities -57.28400M -45.53300M -22.03900M -15.02600M
Issuance of capital stock 51.53M 86.20M 145.21M 31.60M
Depreciation 0.17M 0.11M 0.06M 0.03M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 0.22M 82.97M - -
Other cashflows from financing activities -0.67200M -3.23300M -0.31900M -0.03300M
Change to netincome 10.57M 3.65M 2.23M 0.44M
Capital expenditures 0.05M 0.33M 0.14M 0.19M
Change receivables - - - -
Cash flows other operating -4.64500M -3.00200M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -118.37600M 35.10M - -
Change in working capital -0.93600M -3.77900M 2.12M 2.07M
Stock based compensation 9.50M 3.65M 0.70M 0.19M
Other non cash items 0.64M 1.50M 1.52M 0.14M
Free cash flow -57.33800M -45.86600M -22.17600M -15.21400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RLYB
Rallybio Corp
0.03 3.46% 1.01 - - - 0.83 -1.4122
NVO
Novo Nordisk A/S
-2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corp

234 Church Street, New Haven, CT, United States, 06510

Key Executives

Name Title Year Born
Dr. Martin W. MacKay Ph.D. Co-Founder, CEO & Chairman 1956
Dr. Stephen Uden M.B, M.D. Co- Founder, Pres, COO & Chief Scientific Officer 1958
Mr. Jeffrey M. Fryer CPA Co-Founder, CFO & Treasurer 1970
Ms. Ami Bavishi Head of Investor Relations & Corp. Communications NA
Dr. Steven W. Ryder F.A.C.P, M.D. Chief Medical Officer 1951
Dr. Martin W. MacKay Ph.D. Co-Founder & Executive Chairman 1956
Dr. Stephen Uden M.B, M.D. Co-Founder, President, CEO & Director 1958
Mr. Jonathan I. Lieber M.B.A. CFO & Treasurer 1970
Ms. Ami Bavishi Head of Investor Relations & Corporate Communications NA
Dr. Steven W. Ryder F.A.C.P, M.D. Chief Medical Officer 1952

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions